Translational Drug Development
This eBook focuses on translational science and discovery partnerships that advance novel therapies through a collective momentum, leveraging efficiencies in drug discovery to accelerate nonclinical research and increase clinical success. We will explore how the development of advanced modalities can uncover new vistas of possibilities through a collaborative and holistic approach with a strategic partner.
Chapter 1: Big Momentum for Small Molecules
Start at the finish. Experienced scientists at Charles River will generate a road map for drug discovery. We call it the critical path. What is going to be critical for you to know to actually get your therapy to that end?
Chapter 2: Parallel Paths to Survival
The foundation of Charles River’s holistic approach for rare diseases consists of parallel exploration of three drug modalities: small molecule drug repurposing, antisense oligonucleotides (ASOs), and gene therapy.
Chapter 3: An Integrated Antibody Discovery and Development Ecosystem
At Charles River, scientists with broad experience in this therapeutic area take a collaborative approach to discovering, characterizing, and developing a wide range of Ab types.
Chapter 4: Going for the Gold in Oncology
Patient-derived xenografts (PDX) and a range of analytical tools—including AI- and in silico-based approaches—promise improved treatments for more cancer patients.
Chapter 5: Predictive CNS Data Maximizes Translation
We are committed to developing a comprehensive portfolio of technologies and capabilities to support drug discovery and safety studies for therapies targeting neurological and psychiatric diseases.
Chapter 6: Synthetic Dreams: Data and AI Catalyze Drug Innovation
Charles River suggests ways pharma can ease the transition to AI-driven research and development.